Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Decreases By 15.1%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 31,400 shares, a drop of 15.1% from the December 15th total of 37,000 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 25,600 shares, the days-to-cover ratio is presently 1.2 days.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock traded up $0.14 on Friday, reaching $3.12. 48,509 shares of the stock were exchanged, compared to its average volume of 28,366. The firm has a fifty day moving average price of $3.27 and a two-hundred day moving average price of $3.67. SOPHiA GENETICS has a twelve month low of $2.70 and a twelve month high of $7.37. The stock has a market cap of $203.97 million, a PE ratio of -2.86 and a beta of 1.00. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $15.85 million during the quarter, compared to the consensus estimate of $15.90 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. During the same quarter last year, the company earned ($0.21) earnings per share. Sell-side analysts anticipate that SOPHiA GENETICS will post -0.98 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. boosted its stake in SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after acquiring an additional 86,764 shares during the last quarter. Green Alpha Advisors LLC grew its holdings in shares of SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock worth $145,000 after buying an additional 25,686 shares in the last quarter. Federated Hermes Inc. boosted its holdings in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after purchasing an additional 23,000 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC acquired a new position in SOPHiA GENETICS during the fourth quarter valued at approximately $70,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.